CSNK1α1 mediates malignant plasma cell survival

Leukemia

Volumn 29, Issue 2, 2015, Pages 474-482

  Hu, Y ^a   Song, W ^a   Cirstea, D ^a   Lu, D ^a   Munshi, N C ^a   Anderson, K C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CASEIN KINASE IALPHA; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FAS ASSOCIATED DEATH DOMAIN PROTEIN; INTERLEUKIN 3; LIN9 PROTEIN; PROTEIN; PROTEIN P53; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; PROTEASOME; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY TEST; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYELOMA CELL; NONHUMAN; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; CELL CYCLE; CHEMISTRY; CYTOLOGY; DISEASE COURSE; GENE EXPRESSION PROFILING; GENETICS; LENTIVIRINAE; METABOLISM; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BORONIC ACIDS; BORTEZOMIB; CASEIN KINASE IALPHA; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-3; LENTIVIRUS; MICE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PLASMA CELLS; PLASMACYTOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION;

EID: 84922530173     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.202     Document Type: Article

References (41)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Medi 2011; 364: 1046-1060.
2. Anderson KC. New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ Program 2011; 2011: 184-190.
3. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508-513.
4. Field-Smith A, Morgan GJ, Davies FE. Ther Clin Risk Manag 2006; 2: 271-279.
5. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456-3463.
6. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-1035.
7. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
8. Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001; 414: 768-773.
9. Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G et al. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 2011; 470: 409-413.
10. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 2012; 109: 9545-9550.
11. Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 2005; 17: 675-689.
12. Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010; 16: 1856-1864.
13. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692-1700.
14. Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Wurl PU et al. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 2005; 28: 508-514.
15. Huart AS, MacLaine NJ, Meek DW, Hupp TR. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem 2009; 284: 32384-32394.
16. Huart AS, MacLaine NJ, Narayan V, Hupp TR. Exploiting the MDM2-CK1alpha protein-protein interface to develop novel biologics that induce UBL-kinasemodification and inhibit cell growth. PLoS One 2012; 7: e43391.
17. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003; 1: 1017-1026.
18. Alappat EC, Feig C, Boyerinas B, Volkland J, Samuels M, Murmann AE et al. Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell 2005; 19: 321-332.
19. Beyaert R, Vanhaesebroeck B, Declercq W, Van Lint J, Vandenabele P, Agostinis P et al. Casein kinase-1 phosphorylates the p75 tumor necrosis factor receptor and negatively regulates tumor necrosis factor signaling for apoptosis. J Biol Chem 1995; 270: 23293-23299.
20. Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A et al. Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 2001; 8: 601-611.
21. Zhao Y, Qin S, Atangan LI, Molina Y, Okawa Y, Arpawong HT et al. Casein kinase 1alpha interacts with retinoid X receptor and interferes with agonist-induced apoptosis. J Biol Chem 2004; 279: 30844-30849.
22. Hu Y, Zheng M, Gali R, Tian Z, Topal Gorgun G, Munshi NC et al. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J 2013; 3: e156.
23. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009; 48: 603-614.
24. Rena G, Bain J, Elliott M, Cohen P. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep 2004; 5: 60-65.
25. Tillement V, Lajoie-Mazenc I, Casanova A, Froment C, Penary M, Tovar D et al. Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization. Exp Cell Res 2008; 314: 2811-2821.
26. Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 2008; 68: 5658-5668.
27. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.
28. Reichert N, Wurster S, Ulrich T, Schmitt K, Hauser S, Probst L et al. Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice, and for tumor suppression. Mol Cell Biol 2010; 30: 2896-2908.
29. Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK. Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine 2005; 29: 256-269.
30. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005; 24: 3397-3408.
31. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260-264.
32. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997; 90: 4062-4070.
33. Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 2014; 123: 706-716.
34. Zhu J, Shibasaki F, Price R, Guillemot JC, Yano T, Dotsch V et al. Intramolecular masking of nuclear import signal on NF-AT4 by casein kinase I and MEKK1. Cell 1998; 93: 851-861.
35. Russell M, Lange-Carter CA, Johnson GL. Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1). J Biol Chem 1995; 270: 11757-11760.
36. Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A et al. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response. Clin Cancer Res 2012; 18: 1888-1900.
37. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006; 108: 1698-1707.
38. Teoh G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000; 95: 1039-1046.
39. Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992; 3: 35-41.
40. Blade J, Esteve J. Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients? Med Oncol 2000; 17: 77-84.
41. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-6338.